Skip to main content
EMA grants orphan status to Conatus' PSC drug
10/19/2017

Conatus Pharmaceuticals' IDN-7314 was granted orphan drug designation by the European Medicines Agency as a treatment for patients with primary sclerosing cholangitis. The drug, an orally available pan-caspase protease inhibitor, also received orphan drug designation from the FDA in June.

Full Story: